California State Teachers Retirement System Purchases 7,886 Shares of Rapport Therapeutics (NASDAQ:RAPP)

California State Teachers Retirement System lifted its stake in Rapport Therapeutics (NASDAQ:RAPP) by 1,151.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,571 shares of the company’s stock after acquiring an additional 7,886 shares during the period. California State Teachers Retirement System’s holdings in Rapport Therapeutics were worth $152,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Deutsche Bank AG acquired a new position in Rapport Therapeutics in the 4th quarter worth approximately $41,000. Crestline Management LP purchased a new position in Rapport Therapeutics during the fourth quarter worth approximately $488,000. Virtus ETF Advisers LLC purchased a new position in Rapport Therapeutics during the fourth quarter worth approximately $66,000. Price T Rowe Associates Inc. MD increased its position in shares of Rapport Therapeutics by 9.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company’s stock worth $20,285,000 after purchasing an additional 95,976 shares in the last quarter. Finally, TRV GP V LLC acquired a new stake in shares of Rapport Therapeutics in the fourth quarter valued at about $126,579,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. JMP Securities assumed coverage on Rapport Therapeutics in a report on Tuesday, April 8th. They issued a “market outperform” rating and a $28.00 price target for the company. Citizens Jmp started coverage on Rapport Therapeutics in a research note on Tuesday, April 8th. They set a “mkt outperform” rating for the company. Four research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $32.67.

Rapport Therapeutics Stock Down 7.9%

Shares of NASDAQ RAPP opened at $11.14 on Friday. Rapport Therapeutics has a 52-week low of $6.43 and a 52-week high of $29.74. The business has a 50-day moving average price of $10.51 and a 200 day moving average price of $13.32. The stock has a market cap of $406.59 million and a PE ratio of -3.23.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.09. Sell-side analysts anticipate that Rapport Therapeutics will post -3.65 earnings per share for the current year.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.